BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17359284)

  • 1. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
    Suzuki T; Urano T; Miki Y; Moriya T; Akahira J; Ishida T; Horie K; Inoue S; Sasano H
    Cancer Sci; 2007 May; 98(5):644-51. PubMed ID: 17359284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
    Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
    Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
    Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
    Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the proliferation rate on the course of node negative breast carcinoma].
    Mitze M; Weikel W; Brumm C; Lippold R; Knapstein PG
    Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):299-305. PubMed ID: 7657137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
    Meng J; Lang RG; Fan Y; Fu L
    Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
    Peters MG; Vidal Mdel C; Giménez L; Mauro L; Armanasco E; Cresta C; Bal de Kier Joffé E; Puricelli L
    Oncol Rep; 2004 Nov; 12(5):1143-50. PubMed ID: 15492807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma.
    Pavelic ZP; Pavelic L; Lower EE; Gapany M; Gapany S; Barker EA; Preisler HD
    Cancer Res; 1992 May; 52(9):2597-602. PubMed ID: 1348967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
    Ioachim E
    Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.